Quantcast
Home > Quotes > ONTX
ONTX

Onconova Therapeutics, Inc. Common Stock (ONTX) Quote & Summary Data

$0.5278
*  
0.0072
1.35%
Get ONTX Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading ONTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ONTX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
3
Today's High / Low
$ 0.545 / $ 0.5021
Share Volume
1,511,645
50 Day Avg. Daily Volume
2,850,253
Previous Close
$ 0.535
52 Week High / Low
$ 2.83 / $ 0.3305
Market Cap
41,753,103
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.56

Intraday Chart

Shares Traded

Share Volume:
1,511,645
50 Day Avg. Daily Volume:
2,850,253

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.93

Trading Range

The current last sale of $0.5278 is 59.70% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.545 $ 2.83
 Low: $ 0.5021 $ 0.3305

Company Description (as filed with the SEC)

Onconova Therapeutics, Inc., sometimes referred to as "we" or the "Company," is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule product candidates primarily to treat cancer. Using our proprietary chemistry platform, we have created a library of targeted agents designed to work against cellular pathways important to cancer cells. We believe that the product candidates in our pipeline have the potential to be efficacious in a variety of cancers. We have one Phase 3 clinical-stage product candidate and two other clinical-stage product candidates (one of which is being developed for treatment of acute radiation syndromes) and several preclinical programs. Substantially all of our current effort is focused on our lead product candidate, rigosertib.  ... More ...  

Risk Grade

Where does ONTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.5202
Open Date:
Jun. 19, 2018
Close Price:
$ 0.535
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info